NLS Pharmaceutics Shareholders Approve All Agenda Items
Ticker: NCEL · Form: 6-K · Filed: Oct 8, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-action, filing-update
Related Tickers: NLS
TL;DR
NLS Pharma shareholders greenlit everything at the Oct 3 meeting.
AI Summary
NLS Pharmaceutics Ltd. held an extraordinary shareholders' meeting on October 3, 2024, where all proposed agenda items were approved. This report is filed as a Form 6-K and is incorporated by reference into NLS Pharmaceutics' existing F-3 registration statements.
Why It Matters
The approval of all agenda items at the extraordinary shareholders' meeting indicates shareholder support for the company's proposed actions, which could impact future strategic decisions and operations.
Risk Assessment
Risk Level: low — This filing is a routine report of shareholder meeting results and does not introduce new financial or operational risks.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- October 3, 2024 (date) — Date of extraordinary shareholders' meeting
- Form F-3 (document) — Registration statements incorporated by reference
FAQ
What was the outcome of the extraordinary shareholders' meeting held by NLS Pharmaceutics Ltd. on October 3, 2024?
All agenda items proposed at the extraordinary shareholders' meeting on October 3, 2024, were approved by the shareholders.
What type of filing is this report from NLS Pharmaceutics Ltd.?
This report is a Form 6-K, a Report of Foreign Private Issuer.
Which registration statements does this Form 6-K filing incorporate by reference?
This Form 6-K is incorporated by reference into NLS Pharmaceutics Ltd.'s Registration Statements on Form F-3, specifically File Nos. 333-262489, 333-268690, and 333-269220.
What is the principal executive office address for NLS Pharmaceutics Ltd.?
The principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Does NLS Pharmaceutics Ltd. file annual reports under Form 20-F or Form 40-F?
NLS Pharmaceutics Ltd. files annual reports under Form 20-F.
Filing Stats: 244 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-10-07 18:22:47
Filing Documents
- ea0217013-6k_nlspharma.htm (6-K) — 10KB
- 0001213900-24-086002.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 7, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2